Biofrontera AG (B8F.DE XETRA) jumps to €6.80 on heavy volume: monitor price targets

The B8F.DE stock closed at €6.80 on XETRA on 05 Feb 2026 after a sharp intraday rise and high volume of 45,797 shares. The price moved from an open of €0.37 to a day high of €6.80, driven by intense trading in this small-cap healthcare name. With a market cap of €20,673,478 and average daily volume near 605 shares, the spike pushed relative volume to 75.70. We examine what moved Biofrontera AG, how valuation holds up, and near-term scenarios for traders and longer-term holders.

Price action and high-volume trade

Biofrontera AG (B8F.DE) closed at €6.80 on 05 Feb 2026. The stock registered a reported change of €6.48 and a listed change percentage of 2000.00%. Volume was 45,797 versus an average of 605, signalling unusually heavy trading for this XETRA microcap.

The intraday range ran from €0.30 to €6.80. Such moves can reflect block trades, listings anomalies, or concentrated buying. Investors should note the wide intraday swing and the stock’s low free float relative to shares outstanding of 3,038,430.

Catalysts and company context

Biofrontera AG operates in dermatology and markets products like Ameluz and BF-RhodoLED. There is an ongoing partnership with Maruho Co., Ltd that supports commercial reach in Asia and Europe. Company site and press listings show regular product and regulatory updates source.

We found no single public Reuters headline tied to today’s volume spike, but market participants often react to distribution, licensing, or share-structure news. For company fundamentals and filings see the Biofrontera profile source.

Fundamentals and valuation snapshot

Key metrics show mixed fundamentals. Reported EPS is -0.21 and the trailing P/E is -32.40, reflecting losses. Price-to-sales is 0.64 and book value per share is €0.31, while price-to-book reads 21.73, indicating market price far above reported equity per share.

Liquidity metrics are modest. Current ratio is 1.76 and debt-to-equity is 0.06. Cash per share equals €0.05 and working capital is €7,647,000, underscoring small absolute cash buffers relative to market noise.

Technicals and trading profile

Short-term technicals show the price above the 50-day average of €6.53 but below the 200-day average of €9.19. Year range runs from €0.30 to €22.58. Average volume is 605 while today’s volume was 45,797, giving a relative volume of 75.70, which points to exceptional trading interest.

Such volume surges often bring volatility and slippage. Market makers and retail order flow can widen spreads. Traders should size positions carefully and expect fast price moves.

Meyka AI grade and model forecast

Meyka AI rates B8F.DE with a score out of 100: 58.59 | Grade: C+ | Suggestion: HOLD. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus.

Meyka AI’s forecast model projects a 12-month target of €8.50, versus the current €6.80, implying an upside of 24.97%. Forecasts are model-based projections and not guarantees. Investors should weigh model output against clinical, regulatory, or corporate updates.

Risks and upside opportunities

Upside drivers include product sales growth for Ameluz and expanded licensing in the U.S. and Asia. A successful regulatory outcome or larger distribution deal could lift revenue per share above the current €0.51 TTM.

Risks include continued negative EPS, low free cash, inventory days at 269.35, high volatility, and potential dilution. The small market cap of €20.67m increases sensitivity to single trades and news.

Final Thoughts

B8F.DE stock posted an outsized move into €6.80 on XETRA with 45,797 shares traded, marking it as a high-volume mover on 05 Feb 2026. The spike highlights liquidity-driven volatility rather than a clear fundamental re-rating. Valuation is mixed: negative EPS of -0.21, price-to-sales 0.64, and a high price-to-book at 21.73. Technicals show strength versus the 50-day average but weakness versus the 200-day average. Meyka AI’s model projects a €8.50 12-month target, an implied upside of 24.97% from €6.80. This projection is model-based and not a guarantee. For traders the story is short-term momentum and execution risk. For longer-term investors, monitor sales trends, cash position, and any licensing or regulatory news that could justify sustained valuation support. As an AI-powered market analysis platform, Meyka AI flags B8F.DE for monitoring, not for automatic buying. Always match position size to liquidity and risk tolerance.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.